Results 151 to 160 of about 181,580 (299)

How Do Technologies Affect How We See and Treat Animals? Extending Technological Mediation Theory to Human-animal Relations [PDF]

, 2022
Koen Kramer, F.L.B. Meijboom
openalex   +1 more source

YAP1::TFE3 mediates endothelial‐to‐mesenchymal plasticity in epithelioid hemangioendothelioma

Molecular Oncology, EarlyView.
The YAP1::TFE3 fusion protein drives endothelial‐to‐mesenchymal transition (EndMT) plasticity, resulting in the loss of endothelial characteristics and gain of mesenchymal‐like properties, including resistance to anoikis, increased migratory capacity, and loss of contact growth inhibition in endothelial cells.
Ant Murphy, Samuel Hartzler, Paula A. Vargas Carranza, Shyaman Jayasundara, Madison E. Yates, Nimod D. Janson, Bozhi Liu, Annaleigh Benton, Majid Kazemian, Jason A. Hanna   +9 more
wiley   +1 more source

Flexible Loading Phase Treat-and-Extend Regimen with Faricimab for Neovascular Age-Related Macular Degeneration: A Real-World Study. [PDF]

Biomedicines
Machida A, Kurihara J, Hirata Y, Machida E, Murakami R, Oka A, Yoneda A, Tsuiki E, Oishi A.   +8 more
europepmc   +1 more source

The need for a pragmatic, individualized treat-and-extend (T&E) treatment paradigm for centre-involving diabetic macular oedema. [PDF]

Eye (Lond), 2023
Chaudhary V, Retina Evidence and Trials INternational Alliance (R.E.T.I.N.A.) Study Group.   +1 more
europepmc   +1 more source

Extended report: nail disease in psoriatic arthritis--clinically important, potentially treatable and often overlooked [PDF]

, 2004
Lyn Williamson, Nicola Dalbeth, Joanne L Dockerty, B. C. Gee, R. Weatherall, B. P. Wordsworth   +5 more
openalex   +1 more source

Gut microbiota diversity is prognostic in metastatic hormone receptor‐positive breast cancer patients receiving chemotherapy and immunotherapy

Molecular Oncology, EarlyView.
In this exploratory study, we investigated the relationship between the gut microbiota and outcome in patients with metastatic hormone receptor‐positive breast cancer, treated in a randomized clinical trial with chemotherapy alone or chemotherapy in combination with immune checkpoint blockade.
Andreas Ullern, Kristian Holm, Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Corinna Bang, Bjørn Naume, Johannes R. Hov, Jon Amund Kyte   +7 more
wiley   +1 more source

Predictors of treatment outcomes following treat-and-extend regimen with aflibercept for branch retinal vein occlusion: post-hoc analysis of the PLATON trial. [PDF]

Sci Rep, 2023
Son W, Jeong WJ, Park JM, Kim JY, Ji YS, Sagong M.   +5 more
europepmc   +1 more source

In vitro properties of patient serum predict clinical outcome after high dose rate brachytherapy of hepatocellular carcinoma

Molecular Oncology, EarlyView.
Following high dose rate brachytherapy (HDR‐BT) for hepatocellular carcinoma (HCC), patients were classified as responders and nonresponders. Post‐therapy serum induced increased BrdU incorporation and Cyclin E expression of Huh7 and HepG2 cells in nonresponders, but decreased levels in responders.
Lukas Salvermoser, Jan Niklas Schäfer, Shraga Nahum Goldberg, Philipp Maximilian Kazmierczak, Moritz Nikolaus Gröper, Philipp Franz Linden, Elif Öcal, Tanja Burkard, Stefanie Corradini, Najib Ben Khaled, Moritz Wildgruber, Max Seidensticker, Jens Ricke, Matthias Stechele, Marianna Alunni‐Fabbroni   +14 more
wiley   +1 more source

Aflibercept for Wet Age-Related Macular Degeneration: A Prospective, Randomized Trial Comparing Treat-And-Extend and Fixed Bimonthly Dosing. [PDF]

J Clin Med
Wu KY, Qian SY, Camiré A, Kim DT, Giunta M.   +4 more
europepmc   +1 more source

Poorer outcome of elderly patients treated with extended-field radiotherapy compared with involved-field radiotherapy after chemotherapy for Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group [PDF]

, 2006
Beate Klimm, H.T. Eich, Heinz Haverkamp, Andreas Lohri, P. Koch, F. Boissevain, Guido Trenn, P. Worst, E. Dühmke, R.P. Müller, Konrad Müller-Hermelink, Beate Pfistner, Volker Diehl, Andreas Engert   +13 more
openalex   +1 more source